European Companies Search Engine
EU funding (€196,708): Immunological and Microbiota Priming of the Response to Infection Hor1 Apr 2021 EU Research and Innovation programme "Horizon"
Overview
Text
Immunological and Microbiota Priming of the Response to Infection
Humans acquire a complex community of intestinal microorganisms in early life (gut microbiota), which helps development of the immune system, and which may reduce risk of inflammatory disease. However, these complex microbiota-immune interactions in early life are underexplored and their subsequent influence on susceptibility to infection remains unknown. The Eberl lab recently reported that a temporary intestinal inflammatory state, termed the ‘weaning reaction’, occurs in mice during a specific window in early life (2-4 weeks) in response to the rapid diversification of the gut microbiota. During weaning, the gut microbiota and its metabolites induce a sub-type of T regulatory cells in the intestine (RORγt+ Tregs) which mediate immune tolerance throughout life. Suppression of the microbiota-induced weaning reaction suppresses RORγt+ Tregs and heightens susceptibility to immunopathology such as allergy and colitis in adulthood. However, it is unknown how the weaning reaction influences the later susceptibility and response to infection. IMPRINT will investigate how the gut microbiota influences the immune system in early life to regulate the response to infection in adulthood. Using mice, this project will evaluate the impact of suppressing the weaning reaction on susceptibility to Citrobacter rodentium infection in adulthood. Next, Treg depletion models will be used to examine whether microbiota-induced Tregs during weaning influence susceptibility to C. rodentium infection in adulthood. Finally, metagenomics, metabolomics and add-back experiments will be performed to identify specific bacteria or metabolites that promote induction of Tregs during weaning and modulate subsequent susceptibility to C. rodentium infection. By combining my skills in metagenomics and metabolomics with the host lab’s expertise in intestinal immunology, IMPRINT poses potential to uncover insights into early-life microbiota-immune interactions and the pathogenesis of infectious disease.
Funded Companies:
| Company name | Funding amount |
| Institut Pasteur | €196,708 |
Source: https://cordis.europa.eu/project/id/101026652
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Societe Francophone de Medecine Tropicale et Sante Internationale, Paris, France.
The visualizations for "Institut Pasteur - EU funding (€196,708): Immunological and Microbiota Priming of the Response to Infection"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
